Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.47M Buy
44,445
+533
+1% +$28.9K 1.88% 18
2025
Q4
$2.17M Sell
43,912
-153
-0.3% -$7.14K 1.64% 23
2025
Q3
$1.92M Buy
44,065
+1,318
+3% +$51.5K 1.5% 25
2025
Q2
$1.66M Buy
42,747
+1,266
+3% +$48.4K 1.36% 26
2025
Q1
$1.63M Sell
41,481
-4,279
-9% -$157K 1.43% 26
2024
Q4
$1.56M Buy
45,760
+5,417
+13% +$195K 1.38% 27
2024
Q3
$1.67M Sell
40,343
-849
-2% -$34.7K 1.44% 30
2024
Q2
$1.6M Buy
41,192
+909
+2% +$38.2K 1.51% 27
2024
Q1
$1.74M Buy
+40,283
New +$1.66M 1.72% 22

Other funds holding GSK

Twin City Private Wealth's GSK Position: Q1 2026 in Review

Twin City Private Wealth increased its GSK (GSK) stake by 1.2% in Q1 2026, buying an estimated $28.9K and bringing the position to 44,445 shares worth $2.47M. The position accounts for 1.88% of the portfolio, ranked #18.

Twin City Private Wealth first reported a position in GSK in Q1 2024 and has held it in 9 quarters since. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Twin City Private Wealth held 44,445 shares of GSK worth $2.47M as of Q1 2026.
  • Twin City Private Wealth bought 533 GSK shares in Q1 2026, an estimated $28.9K.
  • GSK made up 1.88% of Twin City Private Wealth's portfolio in Q1 2026, its #18 holding.
  • Twin City Private Wealth first reported a position in GSK in Q1 2024 and has held it in 9 quarters since.
  • 1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Twin City Private Wealth's 13F filing for Q1 2026, filed 24 Apr 2026.